CO6382178A2 - Compuestos anti-angiogénicos dirigidos al factor de crecimiento vascular endotelial - Google Patents

Compuestos anti-angiogénicos dirigidos al factor de crecimiento vascular endotelial

Info

Publication number
CO6382178A2
CO6382178A2 CO10145585A CO10145585A CO6382178A2 CO 6382178 A2 CO6382178 A2 CO 6382178A2 CO 10145585 A CO10145585 A CO 10145585A CO 10145585 A CO10145585 A CO 10145585A CO 6382178 A2 CO6382178 A2 CO 6382178A2
Authority
CO
Colombia
Prior art keywords
endotelial
growth factor
vascular growth
angiogenic compounds
compounds directed
Prior art date
Application number
CO10145585A
Other languages
English (en)
Inventor
Venkata Doppalapudi
Jing-Yu Lai
Bin Liu
Dingguo Liu
Joel Desharnais
Abhijit Suresh Bhat
Yanwen Fu
Bryan Oates
Curt Bradshaw
Original Assignee
Covx Technologies Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covx Technologies Ireland Ltd filed Critical Covx Technologies Ireland Ltd
Publication of CO6382178A2 publication Critical patent/CO6382178A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona péptidos de unión a VEGF. Además, la invención proporciona péptidos VEGF conjugados a anticuerpos solos y junto con otras moléculas antiangiogénicas. Se proporcionan diversos usos de los péptidos y compuestos, incluyendo procedimientos para tratar trastornos asociados a angiogénesis anormal.
CO10145585A 2008-05-05 2010-11-19 Compuestos anti-angiogénicos dirigidos al factor de crecimiento vascular endotelial CO6382178A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5054408P 2008-05-05 2008-05-05
US5056908P 2008-05-05 2008-05-05
US5057408P 2008-05-05 2008-05-05

Publications (1)

Publication Number Publication Date
CO6382178A2 true CO6382178A2 (es) 2012-02-15

Family

ID=40940570

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10145585A CO6382178A2 (es) 2008-05-05 2010-11-19 Compuestos anti-angiogénicos dirigidos al factor de crecimiento vascular endotelial

Country Status (16)

Country Link
US (2) US8293714B2 (es)
EP (1) EP2285415A1 (es)
JP (2) JP5270753B2 (es)
KR (1) KR101302233B1 (es)
CN (1) CN102164616A (es)
AR (1) AR077522A1 (es)
AU (1) AU2009245324B2 (es)
CA (1) CA2722474A1 (es)
CO (1) CO6382178A2 (es)
IL (1) IL209322A (es)
MY (1) MY156767A (es)
NZ (1) NZ589271A (es)
RU (1) RU2511420C2 (es)
TW (1) TW201006496A (es)
WO (1) WO2009136352A1 (es)
ZA (1) ZA201008196B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
RU2012157167A (ru) * 2010-07-12 2014-08-20 КовЭкс Текнолоджиз Айэлэнд Лимитед Полифункциональные антительные конъюгаты
SG190082A1 (en) * 2010-11-05 2013-06-28 Covx Technologies Ireland Ltd Anti-diabetic compounds
WO2012093068A1 (en) 2011-01-03 2012-07-12 F. Hoffmann-La Roche Ag A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide
CA2846030A1 (en) * 2011-08-31 2013-03-07 Indi Molecular, Inc. Vegf-specific capture agents, compositions and methods of using and making
AU2012323849B2 (en) * 2011-10-13 2017-04-20 EyePoint Pharmaceuticals, Inc. Treatment of ocular disease
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
MX2014007500A (es) 2011-12-20 2014-07-28 Pfizer Procesos mejorados para preparar conjugados y enlazadores de peptido.
EP3447071A1 (en) * 2012-01-09 2019-02-27 Pfizer Healthcare Ireland Mutant antibodies and conjugation thereof
HUE056217T2 (hu) 2012-07-13 2022-02-28 Roche Glycart Ag Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében
CA2948810A1 (en) 2014-05-10 2015-11-19 Sorrento Therapeutics, Inc. Chemically-locked bispecific antibodies
SG11201703428SA (en) 2014-11-10 2017-05-30 Hoffmann La Roche Bispecific antibodies and methods of use in ophthalmology
US11059885B2 (en) * 2016-05-13 2021-07-13 Askgene Pharma Inc. Angiopoietin 2, VEGF dual antagonists
JP7387440B2 (ja) * 2016-12-23 2023-11-28 バイスクルテクス・リミテッド Ｍｔ１－ｍｍｐに結合するためのペプチドリガンド
WO2018115203A1 (en) * 2016-12-23 2018-06-28 Bicyclerd Limited Peptide derivatives having novel linkage structures
CN113164597A (zh) 2018-09-24 2021-07-23 爱尔皮奥制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
RU2739246C1 (ru) * 2019-12-26 2020-12-22 Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный университет" (СПбГУ)" Пептиды, связывающие фактор роста эндотелия сосудов
WO2022034523A1 (en) * 2020-08-13 2022-02-17 Immunitybio, Inc. Phagocytosis-inducing compounds and methods of use
CN112986575B (zh) * 2020-12-29 2023-03-17 上海药明康德新药开发有限公司 一种串联式验证dna编码苗头化合物修饰抗体的方法

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US490873A (en) * 1893-01-31 Folding confessional
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
DE2454227C3 (de) * 1974-11-15 1979-05-03 Blaupunkt-Werke Gmbh, 3200 Hildesheim Fernsehempfänger zum Empfang u. Auswerten von zusätzlichen Informationen in einem Fernsehsignal
US4081754A (en) * 1977-01-31 1978-03-28 Jackson Joseph N Programmable television receiver controllers
DE2714501B1 (de) * 1977-04-01 1978-09-07 Grundig Emv Fernsehempfaenger als Bildwiedergabe-Terminal fuer elektronische Peripherie-Gerte
JPS5951054B2 (ja) * 1977-08-25 1984-12-12 ソニー株式会社 記録再生装置
CA1124901A (en) * 1977-12-21 1982-06-01 Masaru Sato Channel selecting apparatus for use with signal receiver and signal recorder
US4435842A (en) * 1978-01-26 1984-03-06 Matsushita Electric Industrial Co., Ltd. Programmable channel selecting apparatus
US4264924A (en) * 1978-03-03 1981-04-28 Freeman Michael J Dedicated channel interactive cable television system
US4193120A (en) * 1978-09-13 1980-03-11 Zenith Radio Corporation Addressable event display and control system
JPS6053967B2 (ja) * 1979-01-11 1985-11-28 ソニー株式会社 放送局の予約可能な受信機
JPS5626286A (en) * 1979-08-10 1981-03-13 Hitachi Ltd Program timer
US4264925A (en) * 1979-08-13 1981-04-28 Michael J. Freeman Interactive cable television system
DE2950432A1 (de) * 1979-12-14 1981-06-19 Edmond 8031 Gröbenzell Keiser Verfahren und vorrichtung zum steuern des betriebs eines fernsehsignalempfaengers
DE3104843A1 (de) * 1981-02-11 1982-08-19 Licentia Patent-Verwaltungs-Gmbh, 6000 Frankfurt Videorecorder mit mehreren bedienungselementen
US4429385A (en) * 1981-12-31 1984-01-31 American Newspaper Publishers Association Method and apparatus for digital serial scanning with hierarchical and relational access
JPS58182326A (ja) * 1982-04-19 1983-10-25 Matsushita Electric Ind Co Ltd プログラムメモリ装置
US4449249A (en) * 1982-09-27 1984-05-15 Price Robert T Televison programming information system
DE3243610A1 (de) * 1982-11-25 1984-05-30 Philips Patentverwaltung Gmbh, 2000 Hamburg Anordnung zur programmierbaren steuerung einer rundfunk- und/oder fernseh-empfangseinrichtung
US4641205A (en) * 1984-03-05 1987-02-03 Rca Corporation Television system scheduler with on-screen menu type programming prompting apparatus
US4573072A (en) * 1984-03-21 1986-02-25 Actv Inc. Method for expanding interactive CATV displayable choices for a given channel capacity
US4751578A (en) * 1985-05-28 1988-06-14 David P. Gordon System for electronically controllably viewing on a television updateable television programming information
US4718107A (en) * 1986-02-14 1988-01-05 Rca Corporation Parental control for CATV converters
DE3625382C2 (de) * 1986-07-26 1994-06-09 Grundig Emv Einrichtung zur Aufzeichnung von Satelliten-Fernsehsendungen
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4832373A (en) * 1987-05-27 1989-05-23 Patricia A. Swan Selective data blocking overlay
DE3819863A1 (de) * 1987-06-12 1989-01-05 Matsushita Electric Ind Co Ltd Fernsteuervorrichtung fuer elektronische geraete
DE3856057T2 (de) * 1987-07-20 1998-10-29 Philips Electronics Nv Fernseh-Übertragungssystem
US4930160A (en) * 1987-09-02 1990-05-29 Vogel Peter S Automatic censorship of video programs
JPH01246978A (ja) * 1988-03-28 1989-10-02 Toshiba Corp 画像情報受信表示装置
US5187589A (en) * 1988-07-28 1993-02-16 Pioneer Electronic Corporation Multiprogram video tape recording and reproducing device
JPH02264586A (ja) * 1989-04-04 1990-10-29 Pioneer Electron Corp Ｃａｔｖシステム及びｃａｔｖ端末装置
US5105184B1 (en) * 1989-11-09 1997-06-17 Noorali Pirani Methods for displaying and integrating commercial advertisements with computer software
JP2811887B2 (ja) * 1990-03-27 1998-10-15 ソニー株式会社 受信装置
AU660926B2 (en) 1990-04-06 1995-07-13 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5619274A (en) * 1990-09-10 1997-04-08 Starsight Telecast, Inc. Television schedule information transmission and utilization system and process
CA2499765C (en) * 1990-09-10 2006-05-09 Starsight Telecast, Inc. User interface for television schedule system
US5526034A (en) * 1990-09-28 1996-06-11 Ictv, Inc. Interactive home information system with signal assignment
US5412720A (en) * 1990-09-28 1995-05-02 Ictv, Inc. Interactive home information system
KR0178536B1 (ko) * 1991-03-11 1999-04-15 강진구 동종 프로그램 채널 선택방법
US5200822A (en) * 1991-04-23 1993-04-06 National Broadcasting Company, Inc. Arrangement for and method of processing data, especially for identifying and verifying airing of television broadcast programs
US5210611A (en) * 1991-08-12 1993-05-11 Keen Y. Yee Automatic tuning radio/TV using filtered seek
US5724203A (en) * 1991-08-19 1998-03-03 Index Systems, Inc. Method and apparatus for determining addresses in time along a recording tape
US5488409A (en) * 1991-08-19 1996-01-30 Yuen; Henry C. Apparatus and method for tracking the playing of VCR programs
US5621579A (en) * 1991-08-19 1997-04-15 Index Systems, Inc. Method for selectively playing back programs recorded on a video tape
US5416508A (en) * 1991-10-22 1995-05-16 Pioneer Electronic Corporation CATV system with transmission of program schedules, linked program broadcasts, and permissive ordering periods
JP3004105B2 (ja) * 1991-11-15 2000-01-31 株式会社東芝 テレビジョン受像機
US5724091A (en) * 1991-11-25 1998-03-03 Actv, Inc. Compressed digital data interactive program system
KR930018994A (ko) * 1992-02-29 1993-09-22 이필곤 T.v 내장용 화상표시회로
US5469206A (en) * 1992-05-27 1995-11-21 Philips Electronics North America Corporation System and method for automatically correlating user preferences with electronic shopping information
US5223924A (en) * 1992-05-27 1993-06-29 North American Philips Corporation System and method for automatically correlating user preferences with a T.V. program information database
US5398074A (en) * 1992-11-24 1995-03-14 Thomson Consumer Electronics, Inc. Programmable picture-outside-picture display
US5592551A (en) * 1992-12-01 1997-01-07 Scientific-Atlanta, Inc. Method and apparatus for providing interactive electronic programming guide
US5600364A (en) * 1992-12-09 1997-02-04 Discovery Communications, Inc. Network controller for cable television delivery systems
ES2154291T3 (es) * 1992-12-09 2001-04-01 Discovery Communicat Inc Controlador de red para sistemas de distribucion de programas de television por cable.
US5631995A (en) * 1993-04-01 1997-05-20 U.S. Philips Corporation Video recorder having circuitry for causing the tuner therein to tune to the same received signal as the tuner in a television receiver connected to the video recorder
US5524195A (en) * 1993-05-24 1996-06-04 Sun Microsystems, Inc. Graphical user interface for interactive television with an animated agent
US5621456A (en) * 1993-06-22 1997-04-15 Apple Computer, Inc. Methods and apparatus for audio-visual interface for the display of multiple program categories
US5594509A (en) * 1993-06-22 1997-01-14 Apple Computer, Inc. Method and apparatus for audio-visual interface for the display of multiple levels of information on a display
FR2709905B1 (fr) * 1993-09-09 1995-10-13 Alcatel Business Systems Système de commande interactive pour installation multiservice disposant d'un serveur de distribution de programmes télévisuels et d'un central téléphonique.
US5410344A (en) * 1993-09-22 1995-04-25 Arrowsmith Technologies, Inc. Apparatus and method of selecting video programs based on viewers' preferences
JP3237362B2 (ja) * 1993-12-27 2001-12-10 松下電器産業株式会社 番組表表示装置
US5592571A (en) * 1994-03-08 1997-01-07 The University Of Connecticut Digital pixel-accurate intensity processing method for image information enhancement
US5733757A (en) 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
US5485219A (en) * 1994-04-18 1996-01-16 Depromax Limited Electric service to record transmissions without recording commercials
US5523796A (en) * 1994-05-20 1996-06-04 Prevue Networks, Inc. Video clip program guide
US5567643A (en) * 1994-05-31 1996-10-22 Taiwan Semiconductor Manufacturing Company Method of forming contamination guard ring for semiconductor integrated circuit applications
US5884028A (en) * 1994-07-29 1999-03-16 International Business Machines Corporation System for the management of multiple time-critical data streams
US5632007A (en) * 1994-09-23 1997-05-20 Actv, Inc. Interactive system and method for offering expert based interactive programs
US5602582A (en) * 1994-11-22 1997-02-11 U S West Marketing Resources Group, Inc. Method and system for processing a request based on indexed digital video data
US5617565A (en) * 1994-11-29 1997-04-01 Hitachi America, Ltd. Broadcast interactive multimedia system
US5758257A (en) * 1994-11-29 1998-05-26 Herz; Frederick System and method for scheduling broadcast of and access to video programs and other data using customer profiles
US5752159A (en) * 1995-01-13 1998-05-12 U S West Technologies, Inc. Method for automatically collecting and delivering application event data in an interactive network
US5517257A (en) * 1995-03-28 1996-05-14 Microsoft Corporation Video control user interface for interactive television systems and method for controlling display of a video movie
US5630119A (en) * 1995-05-05 1997-05-13 Microsoft Corporation System and method for displaying program listings in an interactive electronic program guide
US5606374A (en) * 1995-05-31 1997-02-25 International Business Machines Corporation Video receiver display of menu overlaying video
US5751282A (en) * 1995-06-13 1998-05-12 Microsoft Corporation System and method for calling video on demand using an electronic programming guide
US6388714B1 (en) * 1995-10-02 2002-05-14 Starsight Telecast Inc Interactive computer system for providing television schedule information
US5737028A (en) * 1995-11-01 1998-04-07 International Business Machines Corporation Previous channel listing with cursor controlled user interface for television video displays
US5754771A (en) * 1996-02-12 1998-05-19 Sybase, Inc. Maximum receive capacity specifying query processing client/server system replying up to the capacity and sending the remainder upon subsequent request
US5732216A (en) * 1996-10-02 1998-03-24 Internet Angles, Inc. Audio message exchange system
US6326176B1 (en) 1997-12-18 2001-12-04 The Scripps Research Institute Aldol condensations by catalytic antibodies
US8577205B2 (en) * 1998-07-30 2013-11-05 Tivo Inc. Digital video recording system
US6898762B2 (en) * 1998-08-21 2005-05-24 United Video Properties, Inc. Client-server electronic program guide
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2385888A1 (en) 1999-09-27 2001-04-05 The Regents Of The University Of California Engineering antibodies that bind irreversibly
US6294374B1 (en) 1999-10-08 2001-09-25 The Scripps Research Institute Use of catalytic antibodies for synthesizing epothilone
AU5943201A (en) 2000-05-03 2001-11-12 Amgen Inc Modified peptides as therapeutic agents
US20020016818A1 (en) * 2000-05-11 2002-02-07 Shekhar Kirani System and methodology for optimizing delivery of email attachments for disparate devices
KR20190096450A (ko) * 2000-10-11 2019-08-19 로비 가이드스, 인크. 매체 콘텐츠 배달 시스템 및 방법
RU2316337C2 (ru) * 2001-04-24 2008-02-10 Мерк Патент Гмбх КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α
US20030009766A1 (en) * 2001-07-06 2003-01-09 Koninklijke Philips Electronics N.V. Person-to-person scheduling and notification of automatic program recording for personalized television
US20030045477A1 (en) 2001-07-26 2003-03-06 Fortuna Haviv Peptides having antiangiogenic activity
EP1280122A3 (en) * 2001-07-27 2004-12-29 Sharp Kabushiki Kaisha Learning support system
WO2003059251A2 (en) * 2001-10-22 2003-07-24 The Scripps Research Institute Antibody targeting compounds
KR100735693B1 (ko) * 2001-11-06 2007-07-06 엘지전자 주식회사 방송 수신기와 비디오 콘텐츠 공유 시스템 및 방법
US7474832B2 (en) * 2002-11-21 2009-01-06 International Business Machines Corporation Personal video recording with storage space distributed among remote personal video recorders
GB0230329D0 (en) * 2002-12-31 2003-02-05 British Telecomm Device profile generation
US20050002738A1 (en) * 2003-04-24 2005-01-06 Coflexip S.A. Method for cutting undersea pipeline to length
US8069255B2 (en) * 2003-06-18 2011-11-29 AT&T Intellectual Property I, .L.P. Apparatus and method for aggregating disparate storage on consumer electronics devices
US7603022B2 (en) * 2003-07-02 2009-10-13 Macrovision Corporation Networked personal video recording system
US8438601B2 (en) * 2003-07-02 2013-05-07 Rovi Solutions Corporation Resource management for a networked personal video recording system
US7454120B2 (en) * 2003-07-02 2008-11-18 Macrovision Corporation Methods and apparatus for client aggregation of television programming in a networked personal video recording system
US8528015B2 (en) * 2003-11-06 2013-09-03 Aptiv Digital, Inc. Resource sharing system of set-top boxes
WO2006010057A2 (en) 2004-07-08 2006-01-26 Amgen Inc. Therapeutic peptides
US20060080415A1 (en) * 2004-08-27 2006-04-13 Tu Edgar A Methods and apparatuses for automatically synchronizing a profile across multiple devices
EP2292248A3 (en) 2005-03-03 2011-06-29 CovX Technologies Ireland Limited Anti-angiogenic compounds
US7805741B2 (en) * 2005-09-13 2010-09-28 Cyberlink Corp. Systems and methods for networking digital video recorders
EP1777962A1 (en) * 2005-10-24 2007-04-25 Alcatel Lucent Access/edge node supporting multiple video streaming services using a single request protocol
US8582946B2 (en) * 2005-11-04 2013-11-12 Rovi Guides, Inc. Systems and methods for recording programs using a network recording device as supplemental storage
NZ576751A (en) 2006-11-10 2011-10-28 Covx Technologies Ireland Ltd Anti-angiogenic compounds
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
WO2009088805A2 (en) * 2008-01-03 2009-07-16 The Scripps Research Institute Antibody targeting through a modular recognition domain

Also Published As

Publication number Publication date
IL209322A (en) 2016-11-30
CA2722474A1 (en) 2009-11-12
AU2009245324B2 (en) 2012-07-19
AR077522A1 (es) 2011-09-07
US20120321591A1 (en) 2012-12-20
US20100003267A1 (en) 2010-01-07
ZA201008196B (en) 2012-04-25
TW201006496A (en) 2010-02-16
JP2013035844A (ja) 2013-02-21
JP2011522794A (ja) 2011-08-04
MY156767A (en) 2016-03-31
AU2009245324A1 (en) 2009-11-12
US8937048B2 (en) 2015-01-20
US8293714B2 (en) 2012-10-23
WO2009136352A1 (en) 2009-11-12
WO2009136352A8 (en) 2010-11-25
KR101302233B1 (ko) 2013-09-02
CN102164616A (zh) 2011-08-24
JP5270753B2 (ja) 2013-08-21
NZ589271A (en) 2012-08-31
EP2285415A1 (en) 2011-02-23
RU2511420C2 (ru) 2014-04-10
RU2010149608A (ru) 2012-06-20
KR20110004471A (ko) 2011-01-13

Similar Documents

Publication Publication Date Title
CO6382178A2 (es) Compuestos anti-angiogénicos dirigidos al factor de crecimiento vascular endotelial
CY1122278T1 (el) Αντι il-36r αντισωματα
EP2560684A4 (en) FIBRONECTIN TYPE III DOMAIN MULTIMERIC SCAFFOLDS
MX2014004457A (es) Uso de moleculas de enlace a semaforina-4d para la modulacion de la permeabilidad de la barrera sangre-cerebro.
WO2009056631A3 (en) Molecules and methods for modulating complement component
MX2015013170A (es) Proteinas de union especificas duales dirigidas contra tnf alpha.
SG195196A1 (en) Dual targeting
WO2010138814A3 (en) Disrupting fcrn-albumin interactions
MX2015011769A (es) Compuestos y sus usos para modular la hemoglobina.
MX359449B (es) Conjugados de anticuerpo fármaco anti-cd70.
WO2012007324A3 (en) Stabilized factor viii variants
EP2590671A4 (en) IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAIN AND USES THEREOF
WO2012100229A3 (en) Compositions and methods for cardiovascular disease
DOP2010000369A (es) Inmunoglobulinas con dominio variable dual y usos de la misma
WO2013102042A3 (en) Dual variable domain immunoglobulins against il-13 and/or il-17
WO2012149440A3 (en) Therapeutic nuclease compositions and methods
MY162323A (en) Anticoagulant antidotes
CR20110103A (es) Heteroarilos sustituidos
AU2016219704A1 (en) Anti-Notch1 antibodies
WO2014078866A3 (en) Engineered immunoglobulins with extended in vivo half-life
UY33124A (es) Agentes y epítopos enlazados a wise
WO2012138599A3 (en) Hepatocyte growth factor mimics as therapeutic agents
BR112015000188A2 (pt) isolados de proteína de batata
CL2013003377A1 (es) Conjugado polipeptídico que comprende un componente polipeptídico covalentemente unido a una fracción que aumenta la duración; composición farmacéutica que comprende un conjugado polipeptídico; método para tratar una enfermedad o desorden en un sujeto.
UY33997A (es) Moléculas de unión biespecíficas que se unen a dii4 y ang2

Legal Events

Date Code Title Description
FG Application granted